- Home
- IRON vs ADAMM Comparison
IRON vs ADAMM Comparison
Compare IRON & ADAMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- ADAMM
- Stock Information
- Founded
- IRON 2017
- ADAMM N/A
- Country
- IRON United States
- ADAMM United States
- Employees
- IRON N/A
- ADAMM N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- ADAMM Real Estate Investment Trusts
- Sector
- IRON Health Care
- ADAMM Real Estate
- Exchange
- IRON Nasdaq
- ADAMM Nasdaq
- Market Cap
- IRON 2.0B
- ADAMM 2.3B
- IPO Year
- IRON N/A
- ADAMM N/A
- Fundamental
- Price
- IRON $59.82
- ADAMM $25.13
- Analyst Decision
- IRON Strong Buy
- ADAMM
- Analyst Count
- IRON 10
- ADAMM 0
- Target Price
- IRON $97.80
- ADAMM N/A
- AVG Volume (30 Days)
- IRON 301.7K
- ADAMM N/A
- Earning Date
- IRON 11-11-2025
- ADAMM N/A
- Dividend Yield
- IRON N/A
- ADAMM N/A
- EPS Growth
- IRON N/A
- ADAMM N/A
- EPS
- IRON N/A
- ADAMM N/A
- Revenue
- IRON N/A
- ADAMM N/A
- Revenue This Year
- IRON N/A
- ADAMM N/A
- Revenue Next Year
- IRON N/A
- ADAMM N/A
- P/E Ratio
- IRON N/A
- ADAMM N/A
- Revenue Growth
- IRON N/A
- ADAMM N/A
- 52 Week Low
- IRON $30.82
- ADAMM N/A
- 52 Week High
- IRON $68.73
- ADAMM N/A
- Technical
- Relative Strength Index (RSI)
- IRON 50.30
- ADAMM N/A
- Support Level
- IRON $58.59
- ADAMM N/A
- Resistance Level
- IRON $61.27
- ADAMM N/A
- Average True Range (ATR)
- IRON 2.13
- ADAMM 0.00
- MACD
- IRON -0.15
- ADAMM 0.00
- Stochastic Oscillator
- IRON 18.47
- ADAMM 0.00
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.